New Zealand markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
84.67+0.20 (+0.24%)
At close: 4:00PM EDT
84.52 -0.15 (-0.18%)
Pre-market: 08:48AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close84.47
Open84.62
Bid84.50 x 800
Ask84.47 x 2900
Day's range84.16 - 84.85
52-week range77.04 - 98.52
Volume2,156,675
Avg. volume1,935,635
Market cap189.385B
Beta (5Y monthly)0.55
PE ratio (TTM)21.45
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.20 (3.78%)
Ex-dividend date04 Mar 2021
1y target estN/A
All
News
  • GlobeNewswire

    Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer

    Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care Facilitated by Novartis, Invisible Nation will aim to reduce and ultimately prevent many of the 15 million1 ASCVD deaths each year and dramatically lower what is estimated to become $1 trillion in annual CV disease care cost by 20302Network members will engage policymakers, healthcare syste

  • GlobeNewswire

    Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics

    Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporinsAcquisition confirms Sandoz commitment to antibiotics, following announcement of further investment plans for European-based manufacturing network Basel, October 11, 2021 – Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotic

  • GlobeNewswire

    Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

    Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Department of Justice (DOJ) concerning the Department’s years-long pricing investigation into the U.S. generic drug industry. This settlement is an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regard